This study establishes a PET imaging approach using ⁶⁴Cu-labeled CD4-specific nanobody (⁶⁴Cu-CD4-Nb1) to visualize CD4⁺ T cell distribution in tumors. In vivo imaging in humanized mice predicted responses or early resistance to immune checkpoint therapy.
⁶⁴Cu-CD4-Nb1 PET imaging accurately measures spatial dynamics of CD4⁺ T cells, identifies early resistance, and predicts efficacy of checkpoint inhibitor therapies.
Humanized CD4 Knockin (hCD4-KI) mouse model developed by genOway, enabling in vivo imaging of human CD4⁺ T cells with nanobody PET tracers.
Cancer immunotherapy, PET imaging, CD4⁺ T cell tracking, Resistance prediction, Immune response assessment
Humanized Knockin, CD4, PET imaging, Nanobody-based targeting, Immunotherapy monitoring
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
